Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
By L. Lindholm, H. Ibsen, B. Dahlöf, R. Devereux, G. Beevers, U. de Faire, F. Fyhrquist, S. Julius, S. Kjeldsen, Krister Kristiansson and 8 more. The Lancet, 2002
1,637 citations recorded by the source corpus.
Subfields: Cardiology and Cardiovascular Medicine, Radiology, Nuclear Medicine and Imaging
View Paper: https://www.semanticscholar.org/paper/73f17145f3ff36cb48338a74ef0d65d68ed4cadd
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cardiology and Cardiovascular Medicine
- V. Basevi
- A. Goldfine
- W. Hiatt
- Cecilia C. Low Wang
- Daniel W. Jones
- J. Wright
- Connie N. Hess
- S. Hyman
In Radiology, Nuclear Medicine and Imaging
Citations in the corpus
- Standards of Medical Care in Diabetes—2012 (2011, positive): “ARBs also improve cardiovascular outcomes in the subset of patients with hypertension, diabetes, and end-organ injury (52).”
- The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. (2003, background): “Thiazide diuretics, -blockers, ACE inhibitors, ARBs, and CCBs are beneficial in reducing CVD and stroke incidence in patients with diabetes.(33,54,63) The ACE inhibitor– or ARB-based treatments favorably affect the progression of diabetic nephropathy and reduce albuminuria,(55,56) and ARBs have been”
- The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019) (2019, positive): “diabetics with macroangiopathy, the LIFE study showed that ARBs significantly prevented the onset of cardiovascular diseases in comparison with β-blockers [1271].”